Inhibikase Therapeutics (NASDAQ:IKT) just reported results for the fourth quarter of 2023.
Inhibikase Therapeutics reported earnings per share of -64 cents. This was above the analyst estimate for EPS of -85 cents.
The company reported revenue of $1,000.
InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at editor@investorplace.com.
Article printed from InvestorPlace Media, https://investorplace.com/earning-results/2024/03/ikt-stock-earnings-inhibikase-therapeutics-for-q4-of-2023/.
